Tenaya Therapeutics, INC 10-Q quarterly reports

Tenaya Therapeutics reported continued progress in its gene therapy trials for heart disease, but also highlighted significant net losses and the ongoing need for substantial additional funding.

Tenaya Therapeutics reports on clinical trial advancements for TN-201 and TN-401, alongside a net loss of $19.3 million for Q1 2026.

Tenaya Therapeutics reported reduced net losses in Q3 2025, driven by cost-cutting, but its lead gene therapy TN-201 was placed on clinical hold by the FDA.

Tenaya Therapeutics reported a reduced net loss in Q2 2025, driven by cost containment and a recent follow-on offering, as it advances its lead gene therapy candidates for heart disease.

Tenaya Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and cost containment measures.

Tenaya Therapeutics, a clinical-stage biotechnology company, released its third quarter 2024 results, highlighting progress in its gene therapy programs and providing an update on its financial status.

Tenaya Therapeutics reports a net loss of $29.4 million for the second quarter of 2024, alongside updates on clinical programs and cost-saving initiatives.

Tenaya Therapeutics reports a net loss of $32.2 million for the first quarter of 2024, while highlighting progress in its clinical-stage gene therapy programs.